undamentalytics Newsletter
Sign in

Indivior Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Indivior Pharmaceuticals, Inc. had total assets of $1.20bn, total liabilities of $1.30bn and shareholders' equity of −$98.0m. It held $195m in cash against $319m of debt: net debt of $124m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents774316319195305
Receivables—254254253273
Inventory—126167153149
Total current assets—1,257827652800
Goodwill—522—
Total assets—1,7581,3161,2011,332
Accounts payable—39634828
Total current liabilities—1,2819249141,301
Short-term debt—31829488
Long-term debt—2373152900
Total debt0240333319488
Total liabilities—1,9421,6521,3001,392
Shareholders' equity−15−184−337−98−60
Net debt (negative = net cash)−774−7614124183

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: INDV vs PAHCINDV vs LNTHINDV vs TRLV

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Indivior Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Indivior Pharmaceuticals, Inc.